Figure 2.

Effects of curcumin with gemcitabine or docetaxel on cell viability of PANC-1, MIA PaCa-2 and HPAF-II cells. (A and B) Combinatory effects of curcumin with gemcitabine or docetaxel on cell viability of PANC-1 cells were determined by MTT assay. Data were collected from three independent experiments. (C and D) Isobologram analysis was used to assess the synergistic effects of curcumin with either gemcitabine or docetaxel on PANC-1 cells. The CI values indicate the synergistic effects at different drug combinations. (E and F) Combinatory effects of curcumin with either gemcitabine or docetaxel on cell viability of MIA PaCa-2 cells were determined by MTT assay. (G and H) Isobologram analysis was used to assess the synergism of curcumin with either gemcitabine or docetaxel on MIA PaCa-2 cells. The CI values depict the synergistic effects at indicated combination drugs. (I and J) Combinatory effects of curcumin with either gemcitabine or docetaxel on cell viability of HPAF-II cells were determined by MTT assay. (K and L) Isobologram analysis was conducted to evaluate the synergism of curcumin with gemcitabine or docetaxel on HPAF-II cells. The CI values depict the synergistic effects at different drug combinations. All the experiments were conducted in triplicate. CI, Combination index. 5C: 5 µM curcumin, 2G: 2 µM gemcitabine, 5G: 5 µM gemcitabine, 10G: 10 µM gemcitabine, 5C+2G: 5 µM curcumin plus 2 µM gemcitabine, 5C+5G: 5 µM curcumin in combination with 5 µM gemcitabine, 5C+10G: 5 µM curcumin in combination with 10 µM gemcitabine, 2D: 2 nM docetaxel, 5D: 5 nM docetaxel, 10D: 10 nM docetaxel, 5C+2D: 5 µM curcumin in combination with 2 nM docetaxel, 5C+5D: 5 µM curcumin in combination with 5 nM docetaxel, 5C+10D: 5 µM curcumin in combination with 10 nM docetaxel. *P<0.05, **P<0.01 and ***P<0.001.